Drug design for the treatment of autoimmune diseases by Increasing the binding affinity of IL-۲۱R Protein to IL-۲۱

Increased production of IL۲۱ is a characteristic of some autoimmune diseases, includingsystemic lupus erythematosus and rheumatoid arthritis, which contributes to the production ofautoantibody as well as the pathological features of autoimmune disease. Therefore, in recentresearches, antibodies have been designed with a single specificity (only to bind to interleukin ۲۱) toinhibit this interleukin. Since the use of monoclonal antibodies as large-sized proteins has a highproduction cost and side effects that limit their use, smaller peptides can be designed and selected thatcontain only the binding region of the receptor to the ligand and groups. The sides of this region havethe direction of complete binding of the receptor to the ligand. To reduce the cost of production, theeconomic bacteria E. coli can be used to express the designed peptide. Therefore, in order to limit thebinding of interleukin ۲۱ with its natural receptor on the cell surface, by creating a mutation in theextracellular part of the interleukin ۲۱ receptor (IL-۲۱R), a small peptide is designed that has anincreased tendency to bind to interleukin ۲۱. The binding of the designed peptide to interleukin ۲۱ willprevent its binding to the IL-۲۱R receptor on the cell surface and subsequent signals.

کلیدواژه ها:

Interleukin ۲۱ ، autoimmune disease ، IL-۲۱R receptor ، E. coli bacteria